LENSAR Reports First Quarter 2025 Results and Provides Business Update

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]